mHSPC VL

Categorizing Patients with Hormone-Sensitive Prostate Cancer - Christopher Sweeney

Details
Christopher Sweeney joins Charles Ryan to discuss the topic of hormone-sensitive prostate cancer, specifically concentrating on how clinicians can confront and categorize their patients with the disease. In continuing the ongoing conversation of the optimal approach for a high-volume patient, Dr. Sweeney uses evidence from current clinical trials to outline optional alternatives to abiraterone tre...

Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer - Neeraj Agarwal

Details
In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...

Prostate Cancer Awareness Month September 2019 - US TOO SEA Blue Event - Alicia Morgans

Details
Brenda Martone invites Alicia Morgans to share details on the upcoming Prostate Cancer Awareness Month event in Chicago, put on by Us TOO International, the 15th Annual SEA Blue Chicago Prostate Cancer Walk and Run. SEA Blue is a celebration of life, of those who have risen to the challenge to fight prostate cancer, of the lives that have been lost to the disease, and of the people we will help to...

The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin

Details
Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...

TITAN, TALAPRO-2 And Ongoing Clinical Trials for Prostate Cancer - Neeraj Agarwal

Details
Petros Grivas invites Neeraj Agarwal to discuss the TITAN trial which reported the first interim analysis at ASCO 2019. The TITAN trial is a "Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With metastatic hormone-sensitive prostate cancer (mHSPC). A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The...

Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris

Details
Kim Chi, MD discusses the first results from TITAN, A phase 3 randomized, placebo-controlled, double-blind study of apalutamide (APA) versus placebo (PBO) in men with metastatic hormone-sensitive prostate cancer (mHSPC), with Michael Morris, MD, and Alicia Morgans, MD. TITAN was designed to accrue patients with prior treatment for localized prostate cancer or prior docetaxel for mHSPC were allowed...

Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin

Details
Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...

Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans

Details
Alicia Morgans, MD reviews her recent presentation in a conversation with Charles Ryan, MD. Her presentation covers three main topics including systemic therapies, treatment of the primary and metastases directed therapy. The three main goals of therapy include delay time to progression, delay the other important goals, delay time to initiation of systemic therapy and ultimately cure, especially w...

Contemporary Management of Hormone Sensitive Prostate Cancer - Alicia Morgans

Details
Alicia Morgans presents a lecture on the contemporary management strategies for hormone sensitive prostate cancer with a focus on systemic therapy including chemohormonal approaches and the use of abiraterone for metastatic hormone sensitive disease. In the discussion, Alicia compares and contrasts both the CHAARTED and STAMPEDE data and provides an update on treatment today, including evidence ba...

Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans

Details
Alicia Morgans discusses the role of integrating patients in treatment decisions by incorporating quality of life, in particular when there are multiple treatments available with similar efficacy. Dr. Morgans emphasizes how patients should be included in the conversations and the decisions on treatment selection and considerations on efficacy, safety, and potential toxicities. She reiterates that...